Abstract: Polypeptides are provided having an amino acid sequence at least 50% identical to the amino acid sequence selected from SEQ ID NO: 1-19, and cyclic oligomers of such polypeptides.

Abstract: The disclosure provides polypeptides that bind tripeptide repeat sequences and having an amino acid sequence at least 50%, identical to the amino acid sequence of any one of SEQ ID NO: 1-105, nucleic acids encoding such polypeptides, expression vectors including such nucleic acids, and host cells including such polypeptides, nucleic acids, and/or expression vectors.

Abstract: Polypeptides are provide having an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:1-17, wherein the polypeptide binds to a chlorophyll (Chl) dimer, and scaffolds thereof.

Abstract: Disclosed herein are polypeptides that bind to the epithelial cell adhesion molecule (EpCAM) and programmed death-ligand I (PDL 1) receptors, nucleic acids encoding them, and methods for their use in treating or limited development of cancer, auto immune disease, or inflammation. The disclosure further provides nucleic acids encoding a polypeptide of the disclosure: expression vector comprising a nucleic acid of the disclosure operatively linker to a suitable regulatory control element, host cells comprising a polypeptide, fusion protein, nucleic acid, or expression vector of any embodiment of the disclosure, and pharmaceutical compositions, comprising the polypeptide, fusion protein, nucleic acid, expression vector, or host cell of any embodiment; and a pharmaceutically acceptable carrier.

Abstract: De novo designed proteins with binding activity are disclosed, which were designed starting from a desired functional site and jointly filling in the missing sequence and structure needed to complete the protein, and uses of the binding proteins.

Abstract: Polypeptides including an amino acid sequence at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-3297 are provided, which are capable of forming protein homodimers containing tunable symmetric pockets.